A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

The company made an upfront payment and will provide success-based milestones and royalties in exchange for global rights.

BOSTON--(BUSINESS WIRE)--Newleos Therapeutics, Inc., a clinical stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, today announced the closing of ...

Boston, USA-based Newleos Therapeutics, a neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience treatments with several clinical programs from Swiss major Roche in hand.

RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...

Otolith Labs, a medical technology company developing prescription medical devices for the treatment of vestibular disorders, announced results from an exploratory user study investigating the effect ...

Uptiq proudly announces the launch of the Developer Edition of the AI Workbench, a cutting-edge platform designed to empower developers in creating AI Agents and Agentic applications for the financial ...